Agreement Between Self-Reported Antirheumatic Medications and Pharmaceutical Claims in an Australian Inflammatory Arthritis Cohort
Files
(Published version)
Date
2025
Authors
Lynch, T.
Barrett, C.
Black, R.
Buchbinder, R.
Carroll, G.
Chand, V.
Hill, C.L.
Lassere, M.
Lester, S.
Russell, O.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
ACR Open Rheumatology, 2025; 7(10):e70105-1-e70105-13
Statement of Responsibility
Tom Lynch, Claire Barrett, Rachel Black, Rachelle Buchbinder, Graeme Carroll, Vibhasha Chand, Catherine L. Hill, Marissa Lassere, Sue Lester, Oscar Russell, Premarani Sinnathurai, Lyn March
Conference Name
Abstract
Objective To assess agreement between prescription claims data and self-reported medication use via longitudinal questionnaires in the Australian Rheumatology Association Database inflammatory arthritis cohort and to identify predictors of discordant self-reports. Methods Agreement was determined between longitudinal questionnaire self-reports (2012–2023) of disease-modifying antirheumatic drug (DMARD), glucocorticoid, anti-inflammatory, and analgesic use and Australian reference standard prescription medication dispensing data (Pharmaceutical Benefits Scheme) using Cohen's kappa, sensitivity, positive predictive value (PPV), and negative predictive value (NPV). Analyses were repeated using four look-back windows of dispensing data (1, 3, 6, and 12 months) before each questionnaire to characterize variations in agreement metrics at the individual medication level. Predictors of discordant self-reports were explored using multivariable logistic regression. Results In our study population (N = 3,407, 67% female, 93.7% White, 64.4% with rheumatoid arthritis, 18.5% with psoriatic arthritis, 14.6% with ankylosing spondylitis, 2.6% with juvenile idiopathic arthritis), agreement with prescription claims data was substantial to high for DMARDs (κ 0.67–0.95, sensitivity 0.69–0.96, PPV 0.64–0.96, NPV 0.9–1), substantial for prescription-only nonopioid analgesics and oral prednisolone/prednisone (κ 0.66–0.80, sensitivity 0.65–0.88, PPV 0.68–0.77, NPV 0.93–1), and moderate to substantial for prescription-only opioid analgesics (κ 0.48–0.7, sensitivity 0.57–0.74, PPV 0.36–0.69, NPV 0.94–1). A 3-month look-back window optimized agreement for most medications, whereas 6- and 12-month windows further improved agreement for specific drugs. No consistent predictors of discordant self-reports were identified, though greater self-rated disability severity and poorer overall health showed the most consistent associations with discordance. Conclusion Agreement between self-reported and pharmaceutical claims data was moderate to high. Poorer overall health and disability may impact accuracy of medication self-report.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.